A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat (LBH589) When Administered In Combination With Lenalidomide And Weekly Dexamethasone In Patients With Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Panobinostat (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Jan 2017 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Interim results (n=26) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.